Best Peptides for Weight Loss: What UK Research Shows (2026)

Weight loss peptide research has expanded dramatically since the approval of GLP-1 analogues like semaglutide and tirzepatide, but the peptide research landscape for metabolic and body composition applications extends well beyond the GLP-1 class. This guide reviews the evidence for peptides studied specifically in the context of fat metabolism, energy expenditure, appetite regulation, and body composition improvement — covering both the well-known GLP-1 class and the lesser-known but mechanistically distinct research compounds.

Research disclaimer: All peptides discussed are for laboratory and research use only. None are approved for general weight loss use without prescription where clinically indicated. This content is for educational and research purposes only.

Understanding Peptide Mechanisms for Fat Loss

Peptides target fat loss through several distinct mechanisms, and understanding these differences is essential for selecting the right compounds for a specific research question:

Appetite suppression (GLP-1 pathway): GLP-1 receptor agonists slow gastric emptying, increase satiety signals to the hypothalamus, and reduce ghrelin (the primary hunger hormone). This produces a caloric deficit through reduced food intake — the primary mechanism behind tirzepatide and similar compounds.

Lipolysis enhancement: Growth hormone and IGF-1 directly stimulate adipose tissue lipolysis — the breakdown of stored triglycerides into fatty acids for energy. GH-stimulating peptides (GHRPs, GHRH analogues) increase GH pulsatility, which drives this lipolytic effect preferentially in visceral adipose tissue.

Metabolic rate increase: Growth hormone increases basal metabolic rate by promoting fat oxidation and maintaining lean mass (which is metabolically more active than fat). MOTS-C improves mitochondrial efficiency and metabolic flexibility, potentially increasing fat utilisation at rest and during exercise.

Insulin sensitisation: Improved insulin sensitivity redirects energy substrate utilisation toward fat oxidation and away from fat storage. Several peptides (MOTS-C, some GLP-1 analogues) improve insulin sensitivity independently of weight change, and these effects compound with weight loss to further improve metabolic health.

Appetite/reward pathway modulation: Melanocortin peptides (Melanotan II) activate MC4R receptors that regulate both sexual function and appetite suppression. AOD-9604, a fragment of the growth hormone molecule, was specifically researched for its lipolytic properties without the growth-promoting effects of full-length GH.

Tirzepatide: Dual GIP/GLP-1 Agonist Research

Tirzepatide represents the current frontier of weight loss peptide research — a first-in-class dual agonist of both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Clinical trials have demonstrated weight loss of 15-22.5% of body weight in obese subjects — substantially greater than prior GLP-1 agonists. The SURMOUNT-1 trial (2022) showed 22.5% weight loss over 72 weeks at the highest dose in non-diabetic obese subjects, representing the most significant pharmacological weight loss effect reported in peer-reviewed literature.

The dual mechanism appears genuinely synergistic — GIP receptor activation enhances the GLP-1 effects on insulin secretion and appears to reduce GLP-1’s commonly reported nausea side effect, improving tolerability at doses that would be poorly tolerated with GLP-1 agonism alone. Research into tirzepatide is now expanding from pure weight loss to cardiovascular outcomes, sleep apnoea, metabolic dysfunction-associated steatotic liver disease (MASLD), and heart failure.

Retatrutide: Triple Agonist Research

Retatrutide (GGG tri-agonist) activates three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). Adding glucagon receptor agonism to the dual GIP/GLP-1 mechanism provides additional lipolytic and thermogenic effects — glucagon directly stimulates fatty acid oxidation and increases energy expenditure. Phase 2 trial data (2023) showed retatrutide achieved up to 24.2% weight loss over 48 weeks, with effects still rising at trial end — suggesting a plateau had not yet been reached.

Retatrutide represents a next-generation incretin-based approach that may ultimately exceed tirzepatide’s weight loss efficacy, making it one of the most actively watched compounds in metabolic peptide research.

AOD-9604: The GH Fragment Approach

AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of the C-terminus of human growth hormone — specifically amino acids 177-191 — which contains the lipolytic activity of growth hormone without the insulin-like growth-promoting effects of the full molecule. This targeted approach was designed to capture fat burning without the growth hormone-related side effects of full GH or the anabolic/mitogenic activity.

Research has demonstrated that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) in adipocytes through a pathway involving beta-3 adrenergic receptors, distinct from the IGF-1 pathway activated by full-length growth hormone. In obese animal models, AOD-9604 reduced body fat without affecting blood glucose, insulin levels, or growth parameters — a promising selectivity profile. However, Phase 3 human trials for obesity did not achieve the primary endpoint, leading to development being redirected toward osteoarthritis and cartilage repair applications where different mechanisms operate.

Tesamorelin: Visceral Fat Reduction Research

Tesamorelin is the only GHRH analogue with regulatory approval, specifically for HIV-associated lipodystrophy — a condition involving pathological visceral fat accumulation. Clinical trials demonstrate visceral adipose tissue (VAT) reduction of approximately 15-18% over 26 weeks compared to placebo, confirmed by CT and MRI volumetric measurement. This effect is mechanistically distinct from appetite suppression — tesamorelin increases GH pulsatility, which drives lipolysis specifically in metabolically active visceral adipose tissue.

For researchers studying visceral obesity (which has distinct cardiovascular and metabolic risk implications compared to subcutaneous fat), tesamorelin provides a validated tool for selectively reducing visceral fat while maintaining lean mass — a combination that is difficult to achieve with caloric restriction alone.

GHRP/GHRH Combinations: GH-Mediated Fat Loss Research

Growth hormone’s lipolytic effects — particularly on visceral adipose tissue — have been established for decades. GH stimulates hormone-sensitive lipase in adipocytes, increasing fatty acid release into circulation for oxidation. The decline in GH pulsatility with age directly contributes to the age-related increase in visceral adiposity observed in both sexes.

Ipamorelin combined with CJC-1295 represents the most commonly studied GHRP/GHRH stack for body composition research. Studies in GH-deficient adults and normal-ageing populations show improvements in body fat percentage, visceral fat volume, and lean mass maintenance with GH secretagogue protocols — with the changes being most pronounced in visceral rather than subcutaneous fat compartments. This regional selectivity is a key differentiator from weight loss achieved through caloric restriction alone.

MOTS-C: Mitochondrial Metabolic Research

MOTS-C is a mitochondria-derived peptide that activates AMPK (AMP-activated protein kinase) — the cellular energy sensor that regulates metabolism, fat oxidation, and glucose uptake. In high-fat-diet animal models, MOTS-C administration prevented weight gain and metabolic dysfunction, restored insulin sensitivity, and increased fat oxidation in skeletal muscle. In aged animal models, MOTS-C reversed obesity and restored youthful metabolic profiles.

The mechanism — activating AMPK and improving mitochondrial function — makes MOTS-C conceptually similar to metformin (which also activates AMPK) but through an endogenous peptide pathway. Human pharmacokinetic and efficacy data in weight management contexts remains limited, making this an active area of early-phase research.

Comparing Mechanisms: Which Approach for Which Research Question?

Different research questions require different mechanistic approaches. Researchers designing peptide weight loss studies should match their compound to their specific hypothesis:

If investigating appetite regulation and satiety signalling, GLP-1/GIP agonists (tirzepatide, retatrutide) are the appropriate primary tools — their appetite suppression mechanisms are well-characterised with extensive human data. If studying visceral fat specifically and its metabolic consequences, tesamorelin or GHRP/GHRH combinations offer selective visceral fat reduction without the nausea and gastrointestinal effects of incretin mimetics. If researching mitochondrial metabolism, insulin resistance, or age-related metabolic decline, MOTS-C targets distinct pathways from all other classes. If studying the lipolytic component of growth hormone action in isolation from its growth-promoting effects, AOD-9604 was specifically designed for this purpose. If body composition (fat vs. lean mass changes) is the primary outcome, GH secretagogue combinations (Ipamorelin + CJC-1295) preserve or increase lean mass while reducing fat — a different outcome profile from pure caloric restriction mimetics.

Weight Maintenance vs. Active Weight Loss Research

An emerging area of peptide research is the distinction between weight loss during active treatment and weight maintenance after achieving target weight. GLP-1 agonist data clearly shows that weight regain occurs after cessation — an important finding for understanding whether these compounds address the underlying regulatory set point or merely suppress it during treatment. Research into peptides with different mechanisms (particularly those targeting hypothalamic set point regulation) may shed light on whether durable weight loss is achievable without continuous pharmacological intervention.